1653 related articles for article (PubMed ID: 25631080)
1. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
2. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
Kanagavelu SK; Snarsky V; Termini JM; Gupta S; Barzee S; Wright JA; Khan WN; Kornbluth RS; Stone GW
Vaccine; 2012 Jan; 30(4):691-702. PubMed ID: 22146759
[TBL] [Abstract][Full Text] [Related]
3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
4. Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice.
Liu J; Clayton K; Gao W; Li Y; Zealey C; Budylowski P; Schwartz J; Yue FY; Bie Y; Rini J; Ostrowski M
Vaccine; 2020 Feb; 38(9):2149-2159. PubMed ID: 32014267
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
8. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
[TBL] [Abstract][Full Text] [Related]
9. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
[TBL] [Abstract][Full Text] [Related]
10. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
[TBL] [Abstract][Full Text] [Related]
11. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.
Melchers M; Bontjer I; Tong T; Chung NP; Klasse PJ; Eggink D; Montefiori DC; Gentile M; Cerutti A; Olson WC; Berkhout B; Binley JM; Moore JP; Sanders RW
J Virol; 2012 Mar; 86(5):2488-500. PubMed ID: 22205734
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
Kanagavelu S; Termini JM; Gupta S; Raffa FN; Fuller KA; Rivas Y; Philip S; Kornbluth RS; Stone GW
PLoS One; 2014; 9(2):e90100. PubMed ID: 24587225
[TBL] [Abstract][Full Text] [Related]
13. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.
Hioe CE; Kumar R; Upadhyay C; Jan M; Fox A; Itri V; Peachman KK; Rao M; Liu L; Lo NC; Tuen M; Jiang X; Kong XP; Zolla-Pazner S
Front Immunol; 2018; 9():2441. PubMed ID: 30416503
[TBL] [Abstract][Full Text] [Related]
15. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
[TBL] [Abstract][Full Text] [Related]
16. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
Green TD; Montefiori DC; Ross TM
J Virol; 2003 Feb; 77(3):2046-55. PubMed ID: 12525639
[TBL] [Abstract][Full Text] [Related]
18. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".
Wang Z; Wang SX; Liu SY; Bao ZY; Zhuang DM; Li L; Zhang CH; Zhang L; Li JY; Lu S
Chin Med J (Engl); 2009 Oct; 122(19):2339-45. PubMed ID: 20079137
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]